文献速递淋巴瘤

替沙基奥仑赛治疗复发/难治性滤泡性淋巴瘤成人患者的持久缓解:ELARA试验更新

Durable response after tisagenlecleucel in adults with relapsed/refractory follicular lymphoma: ELARA trial update.
PubMed 文献 · Blood · 2024-01-01

ELARA是一项2期试验,97例复发/难治性滤泡性淋巴瘤(1-3A级)成人患者接受替沙基奥仑赛输注,中位随访29个月。24个月无进展生存率57.4%、缓解持续时间66.4%、总生存率87.7%,完全缓解率68.1%、总缓解率86.2%,未报告新的安全性信号或治疗相关死亡。

要点

  • 中位随访29个月,24个月无进展生存率57.4%、缓解持续时间66.4%、总生存率87.7%
  • 完全缓解率68.1%、总缓解率86.2%,未报告新的安全性信号或治疗相关死亡
  • 肿瘤浸润LAG3+CD3+耗竭T细胞低水平和基线初始CD8+T细胞较高与结局改善相关

核心结论

  • 替沙基奥仑赛在ELARA试验29个月延长随访中持续显示高度持久的疗效和良好的安全性特征。

研究设计与样本

  • 2期ELARA试验纳入97例复发/难治性滤泡性淋巴瘤(1-3A级)成人患者,接受替沙基奥仑赛输注(0.6×10^8-6×10^8个嵌合抗原受体阳性活T细胞),允许桥接化疗。
  • 中位随访29个月(四分位距22.2-37.7),评估长期疗效、安全性、药代动力学和探索性生物标志物。

主要发现

  • 中位无进展生存期、缓解持续时间和总生存期均未达到。
  • 全部患者的估计24个月无进展生存率为57.4%(95%CI 46.2-67)、缓解持续时间率为66.4%(95%CI 54.3-76)、总生存率为87.7%(95%CI 78.3-93.2)。
  • 完全缓解率为68.1%(95%CI 57.7-77.3),总缓解率为86.2%(95%CI 77.5-92.4)。
  • 未报告新的安全性信号或治疗相关死亡。
  • 肿瘤浸润LAG3+CD3+耗竭T细胞低水平和基线初始CD8+T细胞较高水平与结局改善相关。

关键数值与推荐

  • 24个月无进展生存率57.4%(95%CI 46.2-67)。
  • 24个月缓解持续时间率66.4%(95%CI 54.3-76)。
  • 24个月总生存率87.7%(95%CI 78.3-93.2)。
  • 完全缓解率68.1%(95%CI 57.7-77.3),总缓解率86.2%(95%CI 77.5-92.4)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Tisagenlecleucel is approved for adults with relapsed/refractory (r/r) follicular lymphoma (FL) in the third- or later-line setting. The primary analysis (median follow-up, 17 months) of the phase 2 ELARA trial reported high response rates and excellent safety profile in patients with extensively pretreated r/r FL. Here, we report longer-term efficacy, safety, pharmacokinetic, and exploratory biomarker analyses after median follow-up of 29 months (interquartile range, 22.2-37.7). As of 29 March 2022, 97 patients with r/r FL (grades 1-3A) received tisagenlecleucel infusion (0.6 × 108-6 × 108 chimeric antigen receptor-positive viable T cells). Bridging chemotherapy was allowed. Baseline clinical factors, tumor microenvironment, blood soluble factors, and circulating blood cells were correlated with clinical response. Cellular kinetics were assessed by quantitative polymerase chain reaction. Median progression-free survival (PFS), duration of response (DOR), and overall survival (OS) were not reached. Estimated 24-month PFS, DOR, and OS rates in all patients were 57.4% (95% confidence interval [CI], 46.2-67), 66.4% (95% CI, 54.3-76), and 87.7% (95% CI, 78.3-93.2), respectively. Complete response rate and overall response rate were 68.1% (95% CI, 57.7-77.3) and 86.2% (95% CI, 77.5-92.4), respectively. No new safety signals or treatment-related deaths were reported. Low levels of tumor-infiltrating LAG3+CD3+ exhausted T cells and higher baseline levels of naïve CD8+ T cells were associated with improved outcomes. Tisagenlecleucel continued to demonstrate highly durable efficacy and a favorable safety profile in this extended follow-up of 29 months in patients with r/r FL enrolled in ELARA. This trial was registered at www.clinicaltrials.gov as #NCT03568461.

来源:Blood,查看原文。版权归原作者所有。

引用

  1. Dreyling M, Fowler NH, Dickinson M, et al. Durable response after tisagenlecleucel in adults with relapsed/refractory follicular lymphoma: ELARA trial update. Blood. 2024. PMID: 38194692. doi:10.1182/blood.2023021567

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。